#Ghent #Belgium #Vaccine Trials #Nipah Virus #Takushoku University

Groundbreaking Phase 1 Trials for Nipah Virus Vaccine Launch

On June 15, 2026, a distinguished research team led by Professor Misako Yoneda from Takushoku University's Advanced Integrated Research Institute began Phase 1 clinical trials for a Nipah virus vaccine in Belgium. This initiative aims to evaluate the vaccine's safety and its capability to induce immune responses in humans, representing a significant step in combating this deadly infectious disease.

Nipah virus, first identified in Malaysia in 1997, has since emerged sporadically, primarily in South Asia, leading to severe outbreaks characterized by high mortality rates reaching up to 90%. As inter-human transmission is documented, the Nipah virus is classified as a substantial global public health threat. Furthermore, its natural hosts, fruit bats, are widely distributed, raising concerns about potential outbreaks.

Currently, no effective treatments or vaccines exist for Nipah virus infection, underlining the urgency of developing preventive measures.

The Nipah vaccine is a product of international collaborative research, employing the measles virus as a vector. This approach leverages the long-standing safety and efficacy of the measles vaccine, effectively modified to express antigens from the Nipah virus. Notably, prior animal studies using hamsters and monkeys showcased the vaccine’s high protective efficacy, ensuring no development of measles nor viral shedding.

Having completed the manufacturing of clinical trial vaccine formulations and securing the necessary approval from Belgian health authorities, the research team proceeded with the first vaccine doses administered on June 15, 2026.

Background of the Research

Since its identification as an emerging infectious disease in 1999, Nipah virus outbreaks have repeatedly occurred in Bangladesh and India. Its extraordinary fatality rate of 40-75%, with peaks of 90%, alongside confirmed person-to-person transmission, categorizes Nipah virus pathogens as a priority concern by the World Health Organization (WHO) and as Category C bioterrorism agents by the CDC.

The measles vaccine is well-studied, establishing long-term immune responses and demonstrating remarkable safety, reinforcing its utility as a vector for the Nipah vaccine. Starting around 2010, under the leadership of Professor Chieko Kai, the research group developed MV-NiV, which integrates Nipah viral genes into a modified measles virus vector, paving the way for future vaccine applications.

Internationally coordinated efforts have been established, with institutions like Tokyo University, Stanford University, the European Vaccine Initiative (EVI), and the International Centre for Diarrheal Disease Research, Bangladesh (icddr,b) collaborating to facilitate the vaccine’s development. Following the successful funding application to the Coalition for Epidemic Preparedness Innovations (CEPI) in 2019, significant research advancements have been made.

Current Study and Its Implications

The current study involves a vast network of over 15 institutions, implementing rigorous collaborative frameworks, including institutions from Japan and Europe. Prior to initiation, the vaccine formulations demonstrated strong protective effects against Nipah virus in a BSL4 facility compliant with EU regulations, validating both efficacy and safety through extensive primate trials.

The commencement of Phase 1 clinical trials at Ghent University marks a crucial milestone. This phase is dedicated to evaluating both the safety and immunogenicity of the newly developed vaccine, focusing on its potential as a viable preventive measure.

If Phase 1 trials validate the safety and immune responses in humans, subsequent phases will follow in Bangladesh, furthering the project’s significance, especially within outbreak-prone regions.

The expectation surrounding this vaccine, founded upon existing research and the established measles vaccine, is that it will demonstrate high safety profiles while inducing robust immune responses. Notably, the targeted vaccination regime is anticipated to provide effective, long-term immunity, thereby addressing neglected infectious diseases in developing countries affordably and sustainably.

Ultimately, the realization of a Nipah virus vaccine could revolutionize infection control strategies in endemic regions, enhancing global security in the face of deadly viral threats. Such advancements underscore the potential of Japanese research contributions to gain vital international applications in infectious disease prevention, reflecting its broader implication in global health security management.

Conclusion

This innovative study is supported by funding from CEPI and the Japan Agency for Medical Research and Development (AMED) SCARDA, signaling a robust collaboration powering essential global health initiatives. As this project unfolds, the continued focus on vaccine development against high-consequence pathogens like Nipah will be crucial in shaping future public health strategies.